Beranda › Karsinoma Neuroendokrin › California
Uji klinis Karsinoma Neuroendokrin di California
6 studi untuk Karsinoma Neuroendokrin mencari peserta di lokasi di California.
Kota di California
Teks studi resmi (Bahasa Inggris)
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
- Los Alamitos Hematology/Oncology Medical Group, Glendale
- MemorialCare Long Beach Medical Center, Long Beach
- Valkyrie Clinical Trials, Los Angeles
- dan 2 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07080242A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Los Angeles Cancer Network, Los Angeles
- Pih Health Hematology Medical Oncology, Whittier
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06330064A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Duarte
- Crinetics Study Site, Newport Beach
- Crinetics Study Site, Orange
- dan 1 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT07129252A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
- USC Norris Comprehensive Cancer Center, Los Angeles
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT05652686A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- St Joseph Heritage Healthcare, Santa Rosa
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT03093116A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- University of Southern California, Los Angeles
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Des 2025 · NCT06943521Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.